Open Orphan PLC (LON:ORPH) said its Venn Life Sciences drug development subsidiary has been awarded two new contracts that start immediately.
The first will see Venn’s Paris team manage the randomisation and supply management for a coronavirus (COVID-19) trial to be conducted by an unnamed European pharmaceutical company.
The team in Breda, in the Netherlands, meanwhile, will deploy its expertise to deliver process improvements in clinical development for the second new client.
In a statement, Open Orphan chairman Cathal Friel said: "As we come towards the end of 2020, it's wonderful to see all the elements of the Open Orphan business are delivering substantial revenues and both new contract wins and renewal of existing long-term customer contracts."
He added that merger and integration of Open Orphan, Venn and hVIVO, the viral challenge study specialist, was “very much now complete” with the enlarged business now profitable.
“Both Venn and hVIVO are converting their substantial pipeline of work whilst providing a high-quality service to their customers,” explained Friel.
“The Paris team's contract is a further demonstration of our work in the fight against COVID-19 and the contract win by our Dutch Breda team shows how we continue to generate repeat business through our expertise.”
